StockNews.AI
VCYT
StockNews.AI
196 days

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

1. Veracyte will release Q4 and full-year 2024 results on February 24, 2025. 2. A conference call will provide insights into financial performance and business updates. 3. The company focuses on transforming cancer diagnostics using advanced technology.

Earnings
+3.31%Current Return
VS
+0.43%S&P 500
$43.7502/04 09:52 PM EDTEvent Start
$45.202/06 04:22 AM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Neutral?

Upcoming financial results may not significantly alter stock perceptions, similar to past earnings cycles.

How important is it?

Earnings reports are critical for investor sentiment; however, expectations may be already priced in.

Why Short Term?

The earnings release will provide immediate insights affecting stock price in the short run.

Related Companies

VCYT
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2024 after the close of market on Monday, February 24, 2025. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. The conference call will be webcast live from the company’s website and will be available via the following link: https://edge.media-server.com/mmc/p/8em9yd38. A webcast replay will be available following the conclusion of the live broadcast and will be accessible on the company’s website at https://investor.veracyte.com/events-presentations. The conference call dial-ins can be accessed by registering at: https://register.vevent.com/register/BId0a04e7e33824346ad0b7e5eb4eb2525 About Veracyte Veracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).

Related News